Gouty Arthritis (Gout) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 131 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Gouty Arthritis (Gout) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Gouty Arthritis (Gout) - Pipeline Review, H2 2014', provides an overview of the Gouty Arthritis (Gout)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gouty Arthritis (Gout) Overview 10
Therapeutics Development 11
Pipeline Products for Gouty Arthritis (Gout) - Overview 11
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12
Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13
Gouty Arthritis (Gout) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Gouty Arthritis (Gout) - Products under Development by Companies 20
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 22
UMeWorld Limited 22
AstraZeneca PLC 23
Teijin Pharma Limited 24
Novartis AG 25
Chugai Pharmaceutical Co., Ltd. 26
Kissei Pharmaceutical Co., Ltd. 27
Pfizer Inc. 28
Addex Therapeutics Ltd 29
BioCryst Pharmaceuticals, Inc. 30
JW Pharmaceutical Corporation 31
LG Life Sciences, Ltd. 32
Omni Bio Pharmaceutical Inc. 33
CymaBay Therapeutics, Inc. 34
Wellstat Therapeutics Corporation 35
Opsona Therapeutics Ltd. 36
PLx Pharma Inc. 37
Antibe Therapeutics, Inc. 38
Selecta Biosciences, Inc. 39
Polaris Group 40
Celtaxsys, Inc. 41
Delenex Therapeutics AG 42
Immune Response BioPharma, Inc. 43
TWi Pharmaceuticals, Inc. 44
Gouty Arthritis (Gout) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
lesinurad sodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
canakinumab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
febuxostat - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
(lesinurad sodium + allopurinol) - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
(lesinurad sodium + febuxostat) - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
arhalofenate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ulodesine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AC-201 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
RDEA-3170 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
CTX-4430 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RLBN-1001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Uricase-PEG 20 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
KUX-1151 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
URC-102 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
(allopurinol + bucillamine) - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PF-06743649 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
BCIBUGT-003 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PN-XXXX - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PL-4100 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecule Inflammasome Modulator Programme - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
DLX-2323 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
IR-888 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ND-2110 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ND-2158 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ND-346 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Fc-Alpha-1 Antitrypsin - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
FcAAT-3 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
FcAAT-2 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
UR-1102 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
RLBN-2020 Series - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
RLBN-3010 Series - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Anti-S100A9 Monoclonal Antibody - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
ATB-352 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
DLX-2681 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
SEL-212 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Small Molecule to Inhibit IL1R1 for Metabolic Disorders - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
LC-350189 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
ARX-8028 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Small Molecules to Inhibit IRAK4 for Inflammatory Disorders - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
XEN-104 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Gouty Arthritis (Gout) - Recent Pipeline Updates 111
Gouty Arthritis (Gout) - Dormant Projects 121
Gouty Arthritis (Gout) - Discontinued Products 122
Gouty Arthritis (Gout) - Product Development Milestones 123
Featured News & Press Releases 123
Aug 13, 2014: AstraZeneca announces top-line results from the Phase III programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients 123
Jun 05, 2014: Revive Therapeutics Submits Pre-IND Package to the US FDA for Its Gout Drug Candidate, REV-002 124
Apr 25, 2014: Mylan Challenges FDA Ruling on Exclusivity Relating to Celecoxib 124
Apr 17, 2014: Teva Settles Patent Litigation with Pfizer on Celebrex 124
Mar 26, 2014: CymaBay Initiates Arhalofenate Phase 2b Gout Study 125
Feb 20, 2014: Revive Therapeutics Signs Material Transfer Agreement with Japanese Pharmaceutical Company 125
Dec 13, 2013: AstraZeneca announces top-line results from phase III monotherapy study of lesinurad in gout patients 126
Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris 127
Jun 17, 2013: TWi Biotechnology Completes Patient Enrollment For Phase II Trial Of AC-201 For Gout Flare Prophylaxis 128
Mar 15, 2013: Omni Bio's Recombinant Molecule Fc-AAT Shown To Be Effective In Mouse Models Of Gouty Arthritis 128
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 131
Disclaimer 131

List of Tables
Number of Products under Development for Gouty Arthritis (Gout), H2 2014 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Comparative Analysis by Unknown Stage Development, H2 2014 19
Products under Development by Companies, H2 2014 20
Products under Development by Companies, H2 2014 (Contd..1) 21
Gouty Arthritis (Gout) - Pipeline by UMeWorld Limited, H2 2014 22
Gouty Arthritis (Gout) - Pipeline by AstraZeneca PLC, H2 2014 23
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H2 2014 24
Gouty Arthritis (Gout) - Pipeline by Novartis AG, H2 2014 25
Gouty Arthritis (Gout) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 26
Gouty Arthritis (Gout) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 27
Gouty Arthritis (Gout) - Pipeline by Pfizer Inc., H2 2014 28
Gouty Arthritis (Gout) - Pipeline by Addex Therapeutics Ltd, H2 2014 29
Gouty Arthritis (Gout) - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014 30
Gouty Arthritis (Gout) - Pipeline by JW Pharmaceutical Corporation, H2 2014 31
Gouty Arthritis (Gout) - Pipeline by LG Life Sciences, Ltd., H2 2014 32
Gouty Arthritis (Gout) - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 33
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics, Inc., H2 2014 34
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H2 2014 35
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd., H2 2014 36
Gouty Arthritis (Gout) - Pipeline by PLx Pharma Inc., H2 2014 37
Gouty Arthritis (Gout) - Pipeline by Antibe Therapeutics, Inc., H2 2014 38
Gouty Arthritis (Gout) - Pipeline by Selecta Biosciences, Inc., H2 2014 39
Gouty Arthritis (Gout) - Pipeline by Polaris Group, H2 2014 40
Gouty Arthritis (Gout) - Pipeline by Celtaxsys, Inc., H2 2014 41
Gouty Arthritis (Gout) - Pipeline by Delenex Therapeutics AG, H2 2014 42
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H2 2014 43
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H2 2014 44
Assessment by Monotherapy Products, H2 2014 45
Assessment by Combination Products, H2 2014 46
Number of Products by Stage and Target, H2 2014 49
Number of Products by Stage and Mechanism of Action, H2 2014 52
Number of Products by Stage and Route of Administration, H2 2014 54
Number of Products by Stage and Molecule Type, H2 2014 56
Gouty Arthritis (Gout) Therapeutics - Recent Pipeline Updates, H2 2014 111
Gouty Arthritis (Gout) - Dormant Projects, H2 2014 121
Gouty Arthritis (Gout) - Discontinued Products, H2 2014 122